Monday, March 25, 2019
News
NEWS HOME
»
PRN INDIA
Stemedica Cell Technologies Reports Positive Data in Phase I/IIa Study of Allogeneic Stem Cells for Ischemic Stroke
  SocialTwist Tell-a-Friend  
   

- itMSCs were safe and well tolerated in the study -

- Results of the study are supportive of advancing clinical program -      

- Plans are underway to conduct Phase IIb trial following consultation with the FDA -

SAN DIEGO, Jan. 7, 2019 /PRNewswire/ --  Stemedica Cell Technologies, Inc., a clinical-stage biopharmaceutical company developing allogeneic progenitor cell and protein therapeutics for use in treating underserved medical conditions, today announced positive results from its Phase I/IIa clinical study for the treatment of ischemic stroke.

Stemedica_Cell_Technologies_Inc_Logo

In a multi-center, open-label Phase I/IIa study, ischemic tolerant mesenchymal stem cells (itMSCs) achieved safety, tolerability, and preliminary efficacy objectives. The data demonstrated that itMSCs administered intravenously appeared to be safe and well tolerated. No serious adverse events or clinically significant changes in lab and imaging measurements were reported. Results of the study are supportive of advancing the clinical program.

"We are excited to move our ischemic stroke program forward," said  Craig Carlson, Chief Executive Officer of  Stemedica. "Approximately 800,000 people in the U.S. suffer strokes each year and 87% of all strokes are ischemic strokes, costing the U.S. an estimated $34 billion each year in health care services, medicines, and missed days of work.1 There are currently no treatments approved by the FDA to reduce the severity of neurological disabilities resulting from ischemic stroke. Stemedica's itMSCs have the potential to address this significant and unmet need."

"Stemedica's Phase I/IIa clinical results demonstrated product safety as well as preliminary efficacy results indicating potentially significant clinical benefits for patients with ischemic stroke," said Dr. Michael Levy, principal investigator in the study, Chief of Pediatric Neurosurgery at Rady Children's Hospital-San Diego, and Clinical Professor of Surgery at UC San Diego School of Medicine.

"The positive results of this clinical trial give Stemedica important insight into how our hypoxia-induced cGMP-manufactured itMSCs perform within an ischemic environment of stroke brain tissue as it relates to safety and potential efficacy," stated Nikolai Tankovich, M.D., Ph.D., President and Chief Medical Officer of Stemedica. "These results are also interesting in light of the fact that patients enrolled in the study had a minimum post-stroke time of 6 months at baseline with some patients having suffered a stroke more than 20 years prior to treatment."

Following a meeting with the FDA anticipated in the first half of 2019, Stemedica plans to initiate a Phase IIb trial. Detailed safety data and clinical results from the Phase I/IIa study with itMSCs will be published and presented at a future medical conference.

Phase I/IIa Study Design
The Phase I/IIa, multi-center, open-label, two-part study assessed the safety, tolerability, and preliminary efficacy of a single intravenous dose of itMSCs to subjects with ischemic stroke. In the first part of the study, 15 subjects received intravenously one dose of 0.5 million cells per kilogram of itMSCs (n = 5), 1.0 million cells per kilogram of itMSCs (n = 5), or 1.5 million cells per kilogram of itMSCs (n = 5). In the second part of the study, 21 subjects received 1.5 million cells per kilogram of itMSCs. The primary endpoint was the safety of treatment with itMSCs during the twelve-month study period as determined by the incidence and severity of adverse events, clinically-significant changes on clinical laboratory tests, vital signs, physical and neurologic examinations. Additional information about the trial can be found at www.clinicaltrials.gov  with Clinical Trial Identifier NCT01297413.  

About Ischemic Stroke
Ischemic Stroke  is a sudden neurological deficit caused by the occlusion of an artery delivering blood to the brain. When this happens, a part of the brain is deprived of oxygen and nutrients. This deprivation results in a cerebral infarction, which provokes neurological damages that result in severe disabilities or death if it lasts more than several minutes or hours. It is characterized by a quick onset, instantaneously or within minutes, and typically affects one half of the body with hemiplegia and unilateral blindness but also speech impairment.

About  Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of allogeneic progenitor cell, protein and combination therapeutics for underserved medical conditions.  Stemedica has developed a proprietary manufacturing technology platform that produces allogeneic progenitor cell products with intellectual property protection under a low-oxygen, low-tension environment in a cGMP-compliant manufacturing facility.  The company's lead drug candidate, itMSCs, is an allogeneic progenitor cell therapy currently in clinical development for the treatment of ischemic stroke and Alzheimer's disease.  The company's second drug candidate, ischemia-tolerant neural progenitor cells, or itNSCs, is an allogeneic cell therapy currently in development.  In addition, Stemedica is developing progenitor multi-cell therapy (itMSCs and itNSCs) for ischemic stroke, Alzheimer's disease, and central and peripheral neurological diseases.  Also in pre-clinical development is combination therapy using progenitor cells and proteins for Alzheimer's disease.  More information on Stemedica may be found at www.stemedica.com.

"Stemedica Cell Technologies" and the Stemedica logo are registered trademarks of  Stemedica Cell Technologies, Inc.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to our business strategy, timeline and other goals and market for our anticipated products, plans and prospects; statements about our ability to obtain regulatory approval; and statements about potential benefits of our drug product candidates and our technologies.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process; our ability to obtain and maintain regulatory approval of our drug product candidates; our ability to obtain funding for our operations; our plans to research, develop, and commercialize our drug product candidates; our ability to achieve market acceptance of our drug product candidates; unanticipated costs or delays in research, development, and commercialization efforts; the applicability of clinical study results to actual outcomes; the size and growth potential of the markets for our drug product candidates; our ability to successfully commercialize our drug product candidates and the timing of commercialization activities; the rate and degree of market acceptance of our drug product candidates; our ability to develop sales and marketing capabilities; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. These forward-looking statements speak only as of the date hereof. Stemedica disclaims any obligation to update these forward-looking statements.

References:

1 Benjamin EJ, Blaha MJ, Chiuve SE, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2017 update: a report from the American Heart Association.  Circulation. 2017;135:e229-e445.

BUSINESS DEVELOPMENT
Stemedica Cell Technologies, Inc.
David McGuigan
Executive Vice President, Strategy and Business Development
(858) 658-0910
dmcguigan@stemedica.com

or

INVESTORS
Stemedica Cell Technologies, Inc.
Marcie Frank
Senior Vice President, Corporate Administration and Investor Relations
(858) 658-0910
investors@stemedica.com

Logo - https://mma.prnewswire.com/media/804434/Stemedica_Cell_Technologies_Inc_Logo.jpghttps://mma.prnewswire.com/media/804434/Stemedica_Cell_Technologies_Inc_Logo.jpg

More News by PR Newswire India

Tejas Networks Appoints Two New Board of Directors - CB Bhave Appointed as Independent Director and Arnob Roy as Executive Director

Football for Friendship: Brazilian National Team Received Nine Values Cup

Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO

New Boundaries: Hublot Launches the Official ICC Cricket World Cup 2019 Watch and Announces Cricketing Legend Kevin Pietersen as a New Friend of the Brand

Tejas Networks Appoints Two New Board of Directors - CB Bhave Appointed as Independent Director and Arnob Roy as Executive Director

Football for Friendship: Brazilian National Team Received Nine Values Cup

Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO

New Boundaries: Hublot Launches the Official ICC Cricket World Cup 2019 Watch and Announces Cricketing Legend Kevin Pietersen as a New Friend of the Brand

New Boundaries: Hublot Launches the Official ICC Cricket World Cup 2019 Watch and Announces Cricketing Legend Kevin Pietersen as a New Friend of the Brand

Hublot and Ferrari Open a New Chapter in Their Collaboration With the Classic Fusion Ferrari GT Watch

Arçelik to Acquire Singer Bangladesh Operations for $75 Million

Frost & Sullivan Identifies 3 Innovative Tactics that Encourage Accessible Water for All

Legal Sea Foods partners with CP Foods on premium products

YuppTV Bags the Digital Broadcast Rights for VIVO IPL 2019 for Australia, Continental Europe, and South East Asia

Youth's Crushed Legs and Life Saved by Timely Treatment at Parvathy Hospital

Azure Power Puts Over 500 MWs of Solar Power Projects Into Operations in FY19

Global Poker League India's 6 City Teams Unveiled After Bootcamp

The Classic Fusion Ferrari GT Watch Opens a New and Innovative Chapter in the Partnership of Excellence Between Hublot and Ferrari

Aeronutrix's Sports Nutrition Brand Fast&Up Announced as the Official Energy Drink Partner for Procam International Running Events in India

Lear Invests in Israel-Based Maniv Mobility Venture Capital Fund

53rd Edition of the Shankar-Shad Mushaira Takes Place in Delhi

Global Digital Spending Touched $575 Bn in 2018 and is Expected to Grow to a Whopping $1.2 Tn by 2022: Says Zinnov

iPinYou Partners with Weibo to Provide a More Integrated Advertising Solution across Social and Programmatic Platforms

ColorTokens Named Next Gen Security Company of the Year at Cyber Defense Magazine 2019 InfoSec Awards

EcoEnergy Insights Recognized for Growth, Innovation and Leadership: Wins Prestigious Frost & Sullivan Best Practices Award

Malaysia's Sapura Group Announced as Host Operator for World-leading CCW Critical Communications Event

RemoteMyApp adopts IBM Cloud to scale multi-platform gaming service

Frost & Sullivan Identifies Motivators of Growth in the Global Battery Energy Storage Market

Now In The Fifth Year, FoodTrekking Awards Recognize Excellence & Innovation In Food Travel Experiences

Systech Partners With NW Solutions to Deliver Brand Protection Offerings

ThroughPut Welcomes Industrial, Automotive, Telecommunications and Technology Heavy-weights, Dr. Hagen Hultzsch and Robert Alpert, to its prestigious Board of Advisors

eCommerce Channels Find High Penetration for Drug and Medical Device Sales

P.I. Works Commended by Frost & Sullivan for the Exceptional Price-Performance Value of Its Automated Network Management and Capacity Planning Solution

VisualDx's Web-based Clinical Decision Support System Acknowledged by Frost & Sullivan as Best in Class

Visiopharm Earns Acclaim from Frost & Sullivan for Transforming Anatomic Pathology with its Cross-platform Software Solutions

Sasol Offers Support to Cyclone Idai Victims

Grundfos Earns Acclaim from Frost & Sullivan for its Innovation-driven Growth in the Water and Wastewater Pumps Market

China's First Digital Bank, WeBank, introduced the '3O' Paradigm of Open Banking at Money 20/20 Asia

Cognitec's Best-in-class Facial Recognition Solutions Honored by Frost & Sullivan

WENZEL Group Earns Acclaim from Frost & Sullivan for Disrupting the Coordinate Measurement Machine Market with Its SF 87 Shop Floor CMM

The Sunhak Peace Prize Committee is accepting nominations for the 4th Sunhak Peace Prize from March through May 2019

Research from XJTLU advances RNA modification mapping

Trina Solar rolls out four new series of modules, unleashes a new era of mass-produced high-output modules

Nexteer Recognized as Manufacturing Leadership Awards 2019 Winner for Enterprise Integration & Technology Leadership

Frost & Sullivan Recognizes Best-in-class Companies with Prestigious Industry Awards

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
TRS fields 32-year old youngster from Se...
Alliance partners will help winning Siva...
One more held in Gurugram mob attack cas...
#VoteKar: PM Modi tweets 16 times in hal...
Kamal Hassan not to contest polls...
Kanhaiya Kumar to contest from Begusarai...
More...    
 
 Top Stories
After RJP-N, FSF-N warns to quit Ol... 
Kamal Hassan not to contest polls... 
TRS fields 32-year old youngster fr... 
IPL 2019: Pant, bowlers help Delhi ... 
Alliance partners will help winning... 
One more held in Gurugram mob attac... 
Australia: Cyclone Veronica hits we... 
Naveen Patnaik announces nine more ...